Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies

A Ghirardello, A Doria, S Zampieri, R Gerli, E Rapizzi, P F Gambari

Abstract

Objective—To assess the prevalence and clinical and serological associations of anti-ribosomal P protein antibodies (anti-P antibodies) in patients with connective tissue diseases (CTDs) and investigate the immunobiological nature of autoantibody clustering in which anti-P antibodies play a part.

Methods—IgG anti-P antibodies in the sera of 267 patients with CTDs and 31 healthy subjects were analysed by immunoblotting performed on cytoplasmic extract of Raji cells. 60 patients with systemic lupus erythematosus (SLE), 32 systemic sclerosis, 46 primary Sjögren’s syndrome, 16 poly/dermatomyositis, 11 rheumatoid arthritis, 8 undifferentiated CTD, 72 overlap CTD, and 22 primary antiphospholipid syndrome were studied. Anti-P antibodies were affinity purified by elution from nitrocellulose bound antigen and tested by ELISA for their binding activity to cardiolipin.

Results—Anti-P antibodies were detected in 16 (6%) patients and in none of the controls: 12/60 SLE (20%) and 4/80 undifferentiated/overlap patients with CTD (5%). A close association of IgG antibodies with P proteins and with cardiolipin was seen in lupus sera (p=0.0069, odds ratio 18.33). Anti-P antibodies from 9 of 12 anti-P lupus serum samples could be affinity purified and none of the affinity purified fractions cross reacted with ELISA plate coated cardiolipin.

Conclusions—Anti-P immunoreactivity is a specific marker of SLE and lupus-like disease and its detection is recommended as a powerful diagnostic tool. Anti-P antibodies are strongly clustered with IgG anticardiolipin antibodies in lupus sera, even if they are independently elicited. This suggests that their cognate autoantigens play a part in a common pathogenic pathway in SLE.

(Ann Rheum Dis 2000;59:975–981)
Rheumatology revised criteria, 14 32 diffuse or limited scleroderma, 15 46 primary Sjögren’s syndrome, 16 16 polymyositis or dermatomyositis, 17 11 rheumatoid arthritis, 18 eight undifferentiated CTID on the basis of insufficient criteria for classification as a defined CTID, 19 and 72 overlap CTID according to specific clinical manifestations of more than one CTID. Additionally, serum samples from 22 patients with primary antiphospholipid syndrome were tested. 20

At the time of blood sampling, specific drug treatment was registered for all patients. In SLE we also evaluated disease activity according to the doctor’s global assessment. 21 All patients with SLE were evaluated by one rheumatologist (AD). In 35 cases the disease was active.

IgG antibodies to ribosomal P proteins and to other cytoplasmic antigens were detected by western blotting as previously described. 22 Briefly, nuclear and cytoplasmic extracts were prepared from Raji cells cultured in RPMI 1640 containing 10% heat inactivated fetal calf serum (Gibco UK, Ltd), penicillin, and streptomycin, according to McHugh et al. 23 All extraction buffers contained 1 mM phenylmethylsulphonylfluoride (Sigma Chemical Co, St Louis, MO) and 10 µg/ml leupeptin. After two washes in cold phosphate buffered saline (PBS; 10 mM sodium phosphate, 150 mM NaCl, pH 7.4), cells were resuspended at a concentration of 106 nuclei/ml in cold hypertonic phosphate buffer (10 mM sodium phosphate, 10 mM NaCl, pH 7.4) containing 0.5% Triton X-100 for 30–40 minutes on ice. After about 20–30 minutes cells were passed through a 0.2 mm diameter needle cut and saturated with 2% casein in Tris-buffered saline (10 mM Tris, 500 mM NaCl, pH 7.5), for at least one hour at room temperature. After blocking, they were probed with anti-P sera and the respective aCL and G aPL were detected as reported elsewhere. 29 Serum IgG and IgM aCL were measured by ELISA according to the method of Harris. 30 Results were expressed as G antiphospholipid (GPL) and M antiphospholipid (MPL) units obtained from the standard curve built with Harris’ reference sera. The mean value ± 3 SD of 100 healthy subjects (11.6 GPL and 7.5 MPL) was considered as normal.
as the cut off point for both IgG and IgM aCL levels. Lupus anticoagulant (LA) was determined by the diluted Russell viper venom time according to the method of Thiagarajan et al.31

Statistical analysis was performed by two sided Fisher’s exact test. Sensitivity for SLE = (number of anti-P positive patients with SLE/total patients with SLE) × 100. Specificity for SLE (with respect to healthy subjects) = (number of anti-P negative healthy subjects/total healthy subjects) × 100; specificity for SLE (with respect to defined CTDs other than SLE or undifferentiated/overlap CTDs) = (number of anti-P negative patients with CTD/total patients with CTD) × 100. Linear regression analysis was used to evaluate the correlation between the IgG anti-P concentrations in the serum samples and the affinity purified preparations, expressed as optical density arbitrary units.

Results

Sixteen of 267 (6%) patients with CTDs were positive for anti-P antibodies by immunoblotting—12/60 with SLE (20%) and 4/80 with undifferentiated/overlap CTD (5%).

Figure 1 shows representative immunoblots of serum samples from healthy subjects on Raji cytoplasmic extract and fig 2 shows typical immunoblot profiles of anti-P positive SLE sera. Anti-P antibodies were significantly more common in patients with SLE than in healthy subjects (p=0.0068) or in patients with other CTDs (p<0.00001).

Figure 3 shows the sensitivity and specificity of anti-P antibodies detected by immunoblotting for the diagnosis of SLE in our patient group. Patients with primary Sjögren’s syndrome, systemic sclerosis, poly/dermatomyositis, primary antiphospholipid syndrome, rheumatoid arthritis, and matched healthy subjects did not show any serum reactivity towards P proteins.

SLE activity did not correlate with anti-P positivity assessed by the doctor’s global assessment. At the time of blood sampling, the incidence of prominent clinical features in patients with SLE with and without anti-P antibodies was similar. At the time of the study, 16 patients with SLE were receiving no treatment, 20 patients were taking prednisone at a daily dose ≤ of 10 mg and 24 patients at daily doses of >10 mg. Nine patients were also taking immunosuppressants. To exclude the possibility that immunosuppressive treatment might have given false negative results, we collected and tested serum samples from five of the nine patients with SLE when they were not receiving immunosuppressive treatment. The results were the same, both with and without immunosuppressive treatment.

Table 1 reports the association of anti-P antibodies with other autoantibodies in patients with CTD. Anti-P antibodies were not

![Figure 1](https://www.annrheumdis.com)

**Figure 1** Immunoblot analysis of serum samples from healthy donors on cytoplasmic extract of Raji cells resolved on 15% SDS-PAGE. Molecular weight markers are indicated in kilodaltons on the right.
associated with any antinuclear antibodies, neither anti-dsDNA nor anti-Sm antibodies, as confirmed by screening on nuclear blot.

Antiphospholipid antibodies were detected in the serum samples of 33/60 (55%) patients with SLE (IgG aCL in 24, IgM aCL in four, both IgG and IgM in five, LA in four patients always associated with IgG aCL positivity), in 17/37 (46%) patients with UCTD, and in 20/22 (91%) with antiphospholipid syndrome (APS). Five of 60 patients with SLE also fulfilled the diagnostic criteria for APS, having had one or more episodes of venous thrombosis and all being aCL positive. Two of the 14 female patients with SLE who became pregnant after disease onset, had a stillbirth; both were aPL negative during pregnancy complications and at the time of the study. We found no association of aCL with thrombosis or recurrent fetal loss in our patients. Anti-P antibodies were significantly associated with IgG aCL (p=0.0009, odds ratio 18.33, 95% confidence interval 2.180 to 154.2) but not with IgM aCL or LA positivity in patients with SLE (fig 4). Interestingly, none of the anti-P positive lupus patients had antiphospholipid syndrome and none of the serum samples from patients with a diagnosis of primary antiphospholipid syndrome contained anti-P antibodies. In 3/60 (5%) lupus sera, anti-P reactivity was the only specific antibody detected; all these sera were also positive for IgG aCL.

To determine whether the close association of IgG antibodies with P proteins and with cardiolipin in lupus sera was due to cross reactivity, anti-P antibodies were affinity purified from the anti-P positive lupus sera (n=12). Figure 5 shows an example of affinity purification of anti-P antibody from a patient serum. Purified immunoglobulins from nine of 12 lupus sera retained P protein binding activity after acid treatment, and blot densitometric analysis showed that IgG anti-P concentrations in the

Table 1 Frequency of autoantibodies in patients with systemic lupus erythematosus (SLE), undifferentiated/overlap CTD (UCTD), and primary antiphospholipid syndrome (APS) and their association with anti-P antibodies. (All values are expressed as number (%))

<table>
<thead>
<tr>
<th></th>
<th>Total patients</th>
<th>Anti-P positive patients</th>
<th>Anti-P negative patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE (n=60)</td>
<td></td>
<td>(n=12)</td>
<td>(n=48)</td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>38 (63)</td>
<td>8 (67)</td>
<td>30 (63)</td>
</tr>
<tr>
<td>Anti-Sm</td>
<td>17 (28)</td>
<td>2 (17)</td>
<td>15 (31)</td>
</tr>
<tr>
<td>Anti-nRNP</td>
<td>23 (38)</td>
<td>2 (17)</td>
<td>21 (44)</td>
</tr>
<tr>
<td>Anti-Ro/SSA</td>
<td>20 (33)</td>
<td>2 (17)</td>
<td>18 (38)</td>
</tr>
<tr>
<td>Anti-La/SSB</td>
<td>5 (8)</td>
<td>1 (8)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>IgG aCL</td>
<td>29 (48)</td>
<td>11 (92)†</td>
<td>18 (38)</td>
</tr>
<tr>
<td>IgM aCL</td>
<td>9 (15)</td>
<td>3 (25)</td>
<td>6 (13)</td>
</tr>
<tr>
<td>LA</td>
<td>4 (7)</td>
<td>2 (17)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Overlap/UCTD* (n=80)</td>
<td></td>
<td>(n=4)</td>
<td>(n=76)</td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>13 (16)</td>
<td>0</td>
<td>13 (17)</td>
</tr>
<tr>
<td>Anti-Sm</td>
<td>9 (11)</td>
<td>1 (25)</td>
<td>8 (11)</td>
</tr>
<tr>
<td>Anti-nRNP</td>
<td>50 (63)</td>
<td>2 (50)</td>
<td>48 (63)</td>
</tr>
<tr>
<td>Anti-Ro/SSA</td>
<td>22 (28)</td>
<td>2 (50)</td>
<td>20 (26)</td>
</tr>
<tr>
<td>Anti-La/SSB</td>
<td>3 (4)</td>
<td>0</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Anti-Scl70</td>
<td>6 (8)</td>
<td>0</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Anti-Jo-1</td>
<td>2 (3)</td>
<td>0</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Anticentromere</td>
<td>4 (5)</td>
<td>1 (25)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>IgG aCL</td>
<td>17 (46)</td>
<td>4 (100)</td>
<td>13 (33)</td>
</tr>
<tr>
<td>IgM aCL</td>
<td>3 (8)</td>
<td>0</td>
<td>3 (8)</td>
</tr>
<tr>
<td>LA</td>
<td>2 (5)</td>
<td>0</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Primary APS (n=22)</td>
<td></td>
<td>(n=0)</td>
<td>(n=22)</td>
</tr>
<tr>
<td>IgG aCL</td>
<td>19 (86)</td>
<td>0.0</td>
<td>19 (86)</td>
</tr>
<tr>
<td>IgM aCL</td>
<td>8 (36)</td>
<td>0.0</td>
<td>8 (36)</td>
</tr>
<tr>
<td>LA</td>
<td>14 (64)</td>
<td>0.0</td>
<td>14 (64)</td>
</tr>
</tbody>
</table>

*Thirty seven of 80 patients with overlap/UCTD were concomitantly tested for antiphospholipid antibodies.
†Significant at p=0.0009, odds ratio 18.33, 95% confidence interval 2.180 to 154.2.
‡LA = lupus anticoagulant.
affinity purified preparations matched those in the respective serum samples ($r=0.923$, $p<0.0001$); the mean (SD) efficiency of purification was 41.4 (9.5%). Moreover, all the affinity purified fractions had an identical cytoplasmic pattern by indirect immunofluorescence on Hep-2 cells (fine dense granular to homogeneous staining). Affinity purified anti-P fractions, tested on ELISA for IgG aCL activity, did not recognise cardiolipin on ELISA assay, whereas IgG aCL were detected in all serum samples from which anti-P antibodies were purified.

Discussion

The results of this study demonstrate anti-P antibody detection by immunoblotting on cytoplasmic extract from cultured lymphoid cells. By this technique it is possible to determine simultaneously both precipitating and non-precipitating autoantibodies of many different specificities. In particular, ribosomal P proteins can be adequately resolved on one dimensional SDS-PAGE and anti-P reactivity can be easily detected because it produces a peculiar blot pattern by concomitant binding to all three P proteins. Immunoblotting for the detection of anti-P immunoreactivity is most commonly employed on isolated ribosomal proteins and is considered to be the method with the best sensitivity and specificity. Quantitative ELISAs have also been developed to detect circulating anti-P antibodies. Nevertheless, ELISA tests still have some limitations and may give conflicting results. Discordant data on the prevalence of anti-P antibody may be due to differences in the nature and purity of the antigens used (synthetic peptides, recombinant fusion proteins, multiple antigen peptides), in the carrier protein to which the peptide may be conjugated, and in the coupling agent used. For such reasons ELISA techniques are still not standardised and immunoblotting is often applied as a confirmatory test.

In this study we were interested in ascertaining the validity of the immunoblotting method when it is applied to total cytoplasmic extract from cultured cells for detection of anti-P antibodies. In our opinion, unsuitability of immunoblotting for routine analysis of anti-P antibodies is largely overcome by its specificity and easy interpretation of anti-P positivity on cytoblots. In an attempt to verify our proposal.
we screened the serum samples from unselected patients with CTDs and healthy subjects for the presence of anti-P antibody by immunoblotting and validated the method’s sensitivity and specificity in a clinical context. When our method was used the high specificity of anti-P antibody for the diagnosis of SLE within a large cohort of patients with CTDs was confirmed, and the diagnostic value of anti-P antibody screening in patients with CTDs is strongly recommended. In fact, as previously noted, anti-P antibodies were found in SLE with a sensitivity of 20%. The specificity was 100% compared with healthy subjects and patients with defined CTD other than SLE or undifferentiated/overlap CTDs, and 95% compared with patients with undifferentiated/overlap CTDs. Furthermore, anti-P antibodies did not occur in serum samples of patients with scleroderma, primary Sjögren’s syndrome, rheumatoid arthritis, poly/dermatomyositis, and primary APS.

To our knowledge, anti-P antibodies have not previously been investigated in patients with primary APS and the lack of positivity we found is interesting. We confirm that the occasional positivity in patients who do not fulfill the classification criteria of SLE may be predictive of a lupus-like clinical picture.39 40 Of the four anti-P positive patients classified as undifferentiated/overlap CTD, three had clinical or laboratory characteristics of SLE-scleroderma-polymyositis overlap syndrome (two also satisfied Sharp’s diagnostic criteria for mixed CTD) and the fourth had major manifestations suggesting polymyositis/rheumatoid arthritis overlap syndrome. Few case reports of the detection of circulating anti-P antibody in patients with undifferentiated CTD or rheumatoid arthritis have been published.41 42

In our cohort anti-P antibodies were strictly associated with the production of IgG antibodies to cardiolipin. Schneebaum et al found a greater frequency of anticardiolipin activity in the anti-P positive lupus patients.43 This, however, was not statistically significant, probably because of differences in the sensitivity of the method used for detection of anti-P antibodies, in the isotype/s considered, and in patients’ selection criteria. We have shown that such correlation is strong and peculiar to SLE and seems to be confined to a subset of aCL positive patients not at risk from aPL related events. Indeed, in our patients with SLE, thrombotic complications due to aPL were rare. Anti-P antibodies were not associated with any other antinuclear antibodies and were the only antibody specificity in three lupus serum samples, all positive for IgG aCL. In particular, they were not associated either with anti-dsDNA or with anti-Sm antibodies. It is worth noting that we found a relatively high frequency of anti-Sm antibody in lupus patients, probably owing to the short disease duration, the absence of any treatment in some patients, and the increased sensitivity of anti-Sm antibody detection by the addition of Tween 20 in the immunoblotting procedure we used.27

To investigate whether such peculiar clustering derives from possible cross reaction of anti-P antibody with cardiolipin, affinity purified antibodies from nitrocellulose bound P proteins were tested for cardiolipin binding. No cross reactive epitope/s was recognised on ELISA plate coated cardiolipin by affinity purified fractions. These data are in keeping with the lack of anti-P antibody positivity we found in patients with primary APS.

Although we cannot exclude the possibility that additional antibodies specific for conformation(s) of P proteins’ are cross reactive with cardiolipin, it seems likely that the concurrent autoimmune responses against the two antigens are independently elicited rather than mediated by immunological cross reaction. As no homology seems to exist between P proteins and cardiolipin, their concurrence suggests that the two antibody populations are simultaneously produced and possibly implicated in a common pathogenetic pathway. A mechanism which results in antigenic spreading and autoantibody clustering is dysregulation of apoptosis: surface blebs of apoptotic cells are a major immunogenic particle in SLE.44 In ultraviolet induced apoptosis, autoantigens targeted in SLE are clustered in two distinct populations of apoptotic blebs, small blebs containing rough endoplasmic reticulum, ribosomes, and Ro ribonucleoproteins, and large blebs containing nucleosomal DNA, Ro, La, and the small nuclear ribonucleoproteins.45 Thus ribosomal and other cytoplasmic autoantigens seem to cluster independently from the nuclear ones. In this context, the significance of the associated immune response against phospholipids was recently investigated.46

The hypothesis has also been recently proposed that anti-P antibody might have a pathogenic role47 48: P0 protein is expressed on the surface of different types of human cells, including endothelial cells, and affinity purified anti-P0 autoantibodies from patients with SLE recognise the surface expressed cognate antigen.49 It is suggested at present that anti-P antibodies may be a type of anti-endothelial cell antibody and cause a direct vascular injury triggered by the antigenic target expressed on endothelial cell surface.49 Antigenic specificities of anti-endothelial cell antibodies are considered extremely heterogeneous and, recently, Bordron et al proposed that “some may be pathogenic and may even have the potential to induce the production of antiphospholipid antibodies”.49

In summary, our results confirm that anti-P antibody is a specific marker of SLE and lupus-like disease and suggest the reliability and diagnostic utility of anti-P antibody screening by immunoblotting in patients with CTD. The autoimmune response against P proteins is strongly coupled with that against cardiolipin in lupus patients, probably through a common pathogenetic pathway in which the two antibodies are independently recognized. Our data may provide clues about the production and pathogenic role of anti-P antibodies in SLE.
Anti-ribosomal P protein antibodies for diagnosis of SLE